IndraLab
Statements
reach
"Previously, our lab discovered that metastatic ascites cells (28–2) from our orthotopic, syngeneic murine model of ovarian cancer were p53 mutant, compared to p53 wild-type ID8 cells used for tumor induction [6], suggesting interaction with the ovarian microenvironment initiated the development of a TP53 mutation."
reach
"Although P53 is typically considered a “tumor suppressor” protein that binds to and repairs damaged DNA or signals for apoptosis in irreparable cells, missense mutations in TP53 elicit mutant p53 proteins with potential gain-of-function properties that stimulate tumor cell proliferation, migration, invasion, survival, chemoresistance, cancer metabolism and/or tissue architecture disruption [65]."
reach
"This statement could be supported by previous studies showing that S15 phosphorylation of TP53 contributed mutant TP53 stability, thereby prolonging cell viability in ovarian cancer cells, and S392 phosphorylation in mutant TP53 could lead to tumor progression in esophageal squamous cell carcinoma."
reach
"Low p53 RNA levels in both the human and the mouse cell lines suggested that mis-splicing drives nonsense-mediated decay of the mutant p53 mRNA.Our findings in the human samples are consistent with previous studies that did not observe detectable p53 protein in the NCI-H716 cell line as well as experiments that used available human data and in-vitro assays to investigate alternative splicing at this site [42–45]."
reach
"The p53 levels in cyclin D1-HA and FHL2 -/- cells were as high as those in wt MEFs in the absence of treatment, and did not increase in response to doxo, reflecting mutant p53 (XREF_FIG), and similar results were obtained with two independent cyclin D1-HA and FHL2 -/- cell pools (data not shown)."